Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

MT1-MMP as a PET Imaging Biomarker for Pancreas Cancer Management.

Morcillo MÁ, García de Lucas Á, Oteo M, Romero E, Magro N, Ibáñez M, Martínez A, Garaulet G, Arroyo AG, López-Casas PP, Hidalgo M, Mulero F, Martínez-Torrecuadrada J.

Contrast Media Mol Imaging. 2018 Aug 26;2018:8382148. doi: 10.1155/2018/8382148. eCollection 2018.

2.

Afatinib restrains K-RAS-driven lung tumorigenesis.

Moll HP, Pranz K, Musteanu M, Grabner B, Hruschka N, Mohrherr J, Aigner P, Stiedl P, Brcic L, Laszlo V, Schramek D, Moriggl R, Eferl R, Moldvay J, Dezso K, Lopez-Casas PP, Stoiber D, Hidalgo M, Penninger J, Sibilia M, Győrffy B, Barbacid M, Dome B, Popper H, Casanova E.

Sci Transl Med. 2018 Jun 20;10(446). pii: eaao2301. doi: 10.1126/scitranslmed.aao2301.

PMID:
29925635
3.

PanDrugs: a novel method to prioritize anticancer drug treatments according to individual genomic data.

Piñeiro-Yáñez E, Reboiro-Jato M, Gómez-López G, Perales-Patón J, Troulé K, Rodríguez JM, Tejero H, Shimamura T, López-Casas PP, Carretero J, Valencia A, Hidalgo M, Glez-Peña D, Al-Shahrour F.

Genome Med. 2018 May 31;10(1):41. doi: 10.1186/s13073-018-0546-1.

4.

A Tricin Derivative from Deschampsia antarctica Desv. Inhibits Colorectal Carcinoma Growth and Liver Metastasis through the Induction of a Specific Immune Response.

Malvicini M, Gutierrez-Moraga A, Rodriguez MM, Gomez-Bustillo S, Salazar L, Sunkel C, Nozal L, Salgado A, Hidalgo M, Lopez-Casas PP, Novella JL, Vaquero JJ, Alvarez-Builla J, Mora A, Gidekel M, Mazzolini G.

Mol Cancer Ther. 2018 May;17(5):966-976. doi: 10.1158/1535-7163.MCT-17-0193. Epub 2018 Feb 26.

PMID:
29483221
5.

c-RAF Ablation Induces Regression of Advanced Kras/Trp53 Mutant Lung Adenocarcinomas by a Mechanism Independent of MAPK Signaling.

Sanclemente M, Francoz S, Esteban-Burgos L, Bousquet-Mur E, Djurec M, Lopez-Casas PP, Hidalgo M, Guerra C, Drosten M, Musteanu M, Barbacid M.

Cancer Cell. 2018 Feb 12;33(2):217-228.e4. doi: 10.1016/j.ccell.2017.12.014. Epub 2018 Jan 27.

PMID:
29395869
6.

Personalized RNA Medicine for Pancreatic Cancer.

Gilles ME, Hao L, Huang L, Rupaimoole R, Lopez-Casas PP, Pulver E, Jeong JC, Muthuswamy SK, Hidalgo M, Bhatia SN, Slack FJ.

Clin Cancer Res. 2018 Apr 1;24(7):1734-1747. doi: 10.1158/1078-0432.CCR-17-2733. Epub 2018 Jan 12.

PMID:
29330203
7.

Pancreas Cancer Precision Treatment Using Avatar Mice from a Bioinformatics Perspective.

Perales-Patón J, Piñeiro-Yañez E, Tejero H, López-Casas PP, Hidalgo M, Gómez-López G, Al-Shahrour F.

Public Health Genomics. 2017;20(2):81-91. doi: 10.1159/000479812. Epub 2017 Sep 1. Review.

8.

Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models.

Engstrom LD, Aranda R, Lee M, Tovar EA, Essenburg CJ, Madaj Z, Chiang H, Briere D, Hallin J, Lopez-Casas PP, Baños N, Menendez C, Hidalgo M, Tassell V, Chao R, Chudova DI, Lanman RB, Olson P, Bazhenova L, Patel SP, Graveel C, Nishino M, Shapiro GI, Peled N, Awad MM, Jänne PA, Christensen JG.

Clin Cancer Res. 2017 Nov 1;23(21):6661-6672. doi: 10.1158/1078-0432.CCR-17-1192. Epub 2017 Aug 1.

PMID:
28765324
9.

Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab.

Toledo RA, Cubillo A, Vega E, Garralda E, Alvarez R, de la Varga LU, Pascual JR, Sánchez G, Sarno F, Prieto SH, Perea S, Lopéz-Casas PP, López-Ríos F, Hidalgo M.

Oncotarget. 2017 May 23;8(21):35289-35300. doi: 10.18632/oncotarget.13311.

10.

Lurbinectedin induces depletion of tumor-associated macrophages, an essential component of its in vivo synergism with gemcitabine, in pancreatic adenocarcinoma mouse models.

Céspedes MV, Guillén MJ, López-Casas PP, Sarno F, Gallardo A, Álamo P, Cuevas C, Hidalgo M, Galmarini CM, Allavena P, Avilés P, Mangues R.

Dis Model Mech. 2016 Dec 1;9(12):1461-1471. Epub 2016 Oct 20.

11.

Monitoring vascular normalization induced by antiangiogenic treatment with (18)F-fluoromisonidazole-PET.

Hernández-Agudo E, Mondejar T, Soto-Montenegro ML, Megías D, Mouron S, Sanchez J, Hidalgo M, Lopez-Casas PP, Mulero F, Desco M, Quintela-Fandino M.

Mol Oncol. 2016 May;10(5):704-18. doi: 10.1016/j.molonc.2015.12.011. Epub 2015 Dec 22.

12.

Whole Exome Sequencing of Rapid Autopsy Tumors and Xenograft Models Reveals Possible Driver Mutations Underlying Tumor Progression.

Xie T, Musteanu M, Lopez-Casas PP, Shields DJ, Olson P, Rejto PA, Hidalgo M.

PLoS One. 2015 Nov 10;10(11):e0142631. doi: 10.1371/journal.pone.0142631. eCollection 2015.

13.

SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial.

Hidalgo M, Plaza C, Musteanu M, Illei P, Brachmann CB, Heise C, Pierce D, Lopez-Casas PP, Menendez C, Tabernero J, Romano A, Wei X, Lopez-Rios F, Von Hoff DD.

Clin Cancer Res. 2015 Nov 1;21(21):4811-8. doi: 10.1158/1078-0432.CCR-14-3222. Epub 2015 Jul 13. Erratum in: Clin Cancer Res. 2016 Dec 15;22(24):6302.

14.

A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer.

Azaro A, Rodon J, Calles A, Braña I, Hidalgo M, Lopez-Casas PP, Munoz M, Westwood P, Miller J, Moser BA, Ohnmacht U, Bumgardner W, Benhadji KA, Calvo E.

Invest New Drugs. 2015 Jun;33(3):710-9. doi: 10.1007/s10637-015-0241-7. Epub 2015 Apr 24.

PMID:
25902900
15.

Pharmacological inhibition of p38 MAPK reduces tumor growth in patient-derived xenografts from colon tumors.

Gupta J, Igea A, Papaioannou M, Lopez-Casas PP, Llonch E, Hidalgo M, Gorgoulis VG, Nebreda AR.

Oncotarget. 2015 Apr 20;6(11):8539-51.

16.

Metabolomic evaluation of Mitomycin C and rapamycin in a personalized treatment of pancreatic cancer.

Navarrete A, Armitage EG, Musteanu M, García A, Mastrangelo A, Bujak R, López-Casas PP, Hidalgo M, Barbas C.

Pharmacol Res Perspect. 2014 Dec;2(6):e00067. doi: 10.1002/prp2.67. Epub 2014 Aug 24.

17.

Colorectal cancer classification based on gene expression is not associated with FOLFIRI response.

Martinez-Garcia R, Lopez-Casas PP, Rico D, Valencia A, Hidalgo M.

Nat Med. 2014 Nov;20(11):1230-1. doi: 10.1038/nm.3701. No abstract available.

PMID:
25375918
18.

Transcriptional dissection of pancreatic tumors engrafted in mice.

Martinez-Garcia R, Juan D, Rausell A, Muñoz M, Baños N, Menéndez C, Lopez-Casas PP, Rico D, Valencia A, Hidalgo M.

Genome Med. 2014 Apr 16;6(4):27. doi: 10.1186/gm544. eCollection 2014.

19.

Reply: 'Comments on Stromal disrupting effects of nab-paclitaxel in pancreatic cancer'.

Alvarez R, Musteanu M, Garcia-Garcia E, Lopez-Casas PP, Megias D, Guerra C, Muñoz M, Quijano Y, Cubillo A, Rodriguez-Pascual J, Plaza C, de Vicente E, Prados S, Tabernero S, Barbacid M, Lopez-Rios F, Hidalgo M.

Br J Cancer. 2014 Oct 14;111(8):1677-8. doi: 10.1038/bjc.2014.129. Epub 2014 Mar 18. No abstract available.

20.

Integrated next-generation sequencing and avatar mouse models for personalized cancer treatment.

Garralda E, Paz K, López-Casas PP, Jones S, Katz A, Kann LM, López-Rios F, Sarno F, Al-Shahrour F, Vasquez D, Bruckheimer E, Angiuoli SV, Calles A, Diaz LA, Velculescu VE, Valencia A, Sidransky D, Hidalgo M.

Clin Cancer Res. 2014 May 1;20(9):2476-84. doi: 10.1158/1078-0432.CCR-13-3047. Epub 2014 Mar 14.

21.

Stromal disrupting effects of nab-paclitaxel in pancreatic cancer.

Alvarez R, Musteanu M, Garcia-Garcia E, Lopez-Casas PP, Megias D, Guerra C, Muñoz M, Quijano Y, Cubillo A, Rodriguez-Pascual J, Plaza C, de Vicente E, Prados S, Tabernero S, Barbacid M, Lopez-Rios F, Hidalgo M.

Br J Cancer. 2013 Aug 20;109(4):926-33. doi: 10.1038/bjc.2013.415. Epub 2013 Aug 1.

22.

An improved quantitative mass spectrometry analysis of tumor specific mutant proteins at high sensitivity.

Ruppen-Cañás I, López-Casas PP, García F, Ximénez-Embún P, Muñoz M, Morelli MP, Real FX, Serna A, Hidalgo M, Ashman K.

Proteomics. 2012 May;12(9):1319-27. doi: 10.1002/pmic.201100611.

PMID:
22589181
23.

The effects of different endocrine disruptors defining compound-specific alterations of gene expression profiles in the developing testis.

López-Casas PP, Mizrak SC, López-Fernández LA, Paz M, de Rooij DG, del Mazo J.

Reprod Toxicol. 2012 Jan;33(1):106-15. doi: 10.1016/j.reprotox.2011.12.012. Epub 2012 Jan 5.

PMID:
22240090
24.

Prioritizing phase I treatment options through preclinical testing on personalized tumorgraft.

Morelli MP, Calvo E, Ordoñez E, Wick MJ, Viqueira BR, Lopez-Casas PP, Bruckheimer E, Calles-Blanco A, Sidransky D, Hidalgo M.

J Clin Oncol. 2012 Feb 1;30(4):e45-8. doi: 10.1200/JCO.2011.36.9678. Epub 2011 Dec 19. No abstract available.

25.

Gene-expression profiling in pancreatic cancer.

López-Casas PP, López-Fernández LA.

Expert Rev Mol Diagn. 2010 Jul;10(5):591-601. doi: 10.1586/erm.10.43. Review.

PMID:
20629509
26.

New scaffolds for the design of selective estrogen receptor modulators.

Martín-Santamaría S, Rodríguez JJ, de Pascual-Teresa S, Gordon S, Bengtsson M, Garrido-Laguna I, Rubio-Viqueira B, López-Casas PP, Hidalgo M, de Pascual-Teresa B, Ramos A.

Org Biomol Chem. 2008 Oct 7;6(19):3486-96. doi: 10.1039/b806918b. Epub 2008 Aug 4.

PMID:
19082149
27.

Gene silencing by RNAi in mouse Sertoli cells.

González-González E, López-Casas PP, Del Mazo J.

Reprod Biol Endocrinol. 2008 Jul 11;6:29. doi: 10.1186/1477-7827-6-29.

28.

The expression patterns of genes involved in the RNAi pathways are tissue-dependent and differ in the germ and somatic cells of mouse testis.

González-González E, López-Casas PP, del Mazo J.

Biochim Biophys Acta. 2008 May;1779(5):306-11. doi: 10.1016/j.bbagrm.2008.01.007. Epub 2008 Feb 14.

29.

Changes in vinexin expression patterns in the mouse testis induced by developmental exposure to 17beta-estradiol.

Paz M, López-Casas PP, Mazo Jd.

Biol Reprod. 2007 Oct;77(4):605-13. Epub 2007 Jun 20.

PMID:
17582013
30.

Phosphoprotein enriched in astrocytes-15 is expressed in mouse testis and protects spermatocytes from apoptosis.

Mizrak SC, Renault-Mihara F, Párraga M, Bogerd J, van de Kant HJ, López-Casas PP, Paz M, del Mazo J, de Rooij DG.

Reproduction. 2007 Apr;133(4):743-51.

PMID:
17504918
31.

Expression of stress inducible protein 1 (Stip1) in the mouse testis.

Mizrak SC, Bogerd J, Lopez-Casas PP, Párraga M, Del Mazo J, de Rooij DG.

Mol Reprod Dev. 2006 Nov;73(11):1361-6.

PMID:
16894550
32.

Regulation of flotillin-1 in the establishment of NIH-3T3 cell-cell interactions.

López-Casas PP, del Mazo J.

FEBS Lett. 2003 Dec 4;555(2):223-8.

33.

Developmental regulation of expression of Ran/M1 and Ran/M2 isoforms of Ran-GTPase in mouse testis.

López-Casas PP, López-Fernández LA, Párraga M, Krimer DB, del Mazo J.

Int J Dev Biol. 2003 May;47(4):307-10.

34.

Ran GTPase expression during early development of the mouse embryo.

López-Casas PP, López-Fernández LA, Krimer DB, del Mazo J.

Mech Dev. 2002 Apr;113(1):103-6.

Supplemental Content

Loading ...
Support Center